What is BioRestorative Therapies Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioRestorative Therapies's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioRestorative Therapies's Operating Income for the
three
months ended in Dec. 2023 was $ -3.22 Mil. BioRestorative Therapies's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
BioRestorative Therapies has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BioRestorative Therapies Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (NAS:BRTX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
BioRestorative Therapies's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-3.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $0.00 Mil.
BioRestorative Therapies's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| BioRestorative Therapies had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. BioRestorative Therapies Inc has enough cash to cover all of its debt. Its financial situation is stable.
BioRestorative Therapies (BioRestorative Therapies) Business Description
Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Executives
| Dale Broadrick |
10 percent owner |
3003 BRICK CHURCH PIKE, NASHVILLE TN 37207 |
| Lance Alstodt |
director, 10 percent owner, officer: President, CEO, COB |
BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747 |
| Francisco Silva |
director, 10 percent owner, officer: VP of Research and Development |
STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458 |
| Robert Eugene Kristal |
officer: Chief Financial Officer |
4719 COLE AVENUE, DALLAS TX 75205 |
| Patrick F. Williams |
director |
C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588 |
| David A Rosa |
director |
10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343 |
| Nickolay V. Kukekov |
director |
4524 WESTWAY AVE, DALLAS TX 75205 |
| Mark Weinreb |
director, 10 percent owner, officer: CEO and Chairman of the Board |
STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458 |
| Paul Jude Tonna |
director |
69 CHICHESTER ROAD, HUNTINGTON NY 11743 |
| A. Jeffrey Radov |
director |
8 WALWORTH AVENUE, SCARSDALE NY 10583 |
| Robert Paccasassi |
officer: VP, Quality and Compliance |
C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747 |
| Robert B Catell |
director |
62 OSBORNE ROAD, GARDEN CITY NY 11530 |
| Adam D. Bergstein |
officer: SVP, Planning and Business Dev |
167 HAZEL AVENUE, GLENCOE IL 60022 |
| John M Desmarais |
director |
230 PARK AVENUE, NEW YORK NY 10169 |
| Westbury Trust |
10 percent owner |
VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000 |
BioRestorative Therapies (BioRestorative Therapies) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BRTX has been successfully added to your 